Common Stock, Par Value $0.001 per share
- Symbol
- AGIO
- Exchange
- NASDAQ
- Classification
- COMMON
- Status
- Current
Current Report · Items 2.02, 9.01 · 8-K
Agios Pharmaceuticals, Inc.
AGIONASDAQEQUITYCurrent
Results of Operations and Financial Condition
Item 2.02 Results of Operations and Financial Condition. On July 30, 2026, Agios Pharmaceuticals, Inc. issued a press release announcing its results for the quarter ended June 30, 2026 and other business highlights. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.…
Press release in this filing
Agios Reports Second Quarter 2026 Financial Results and Provides Business Update →Company context
At Agios, our vision is to redefine the future of rare disease treatment. Fueled by connections, we build trusted partnerships with communities - collaborating to develop and deliver innovative medicines that have the potential to transform lives. With a foundation in hematology, we combine biological expertise with real-world insights to advance a growing pipeline of rare disease medicines that reflect the priorities of the people we serve. Agios is a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts. To learn more, visit www.agios.com and follow us on LinkedIn and X.
Current securities
Registered securities in this filing
Agios Pharmaceuticals, Inc. · 8-K · Filed 2026-07-30
Disclosure sections
Item 2.02Item 2.02 - Results of Operations
Item 2.02 Results of Operations and Financial Condition.
On July 30, 2026, Agios Pharmaceuticals, Inc. issued a press release announcing its results for the quarter ended June 30, 2026 and other business highlights. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.
The information in this Form 8-K, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.